Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Environmental Management|April 7, 2020
Conceptualizing alternate regimes in a large floodplain-river ecosystem: Water clarity, invasive fish, and floodplain vegetationKristen L Bouska, Jeffrey N Houser, Nathan R De Jager, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
European Journal of Cancer & Clinical Oncology|November 1, 1984
An EORTC phase II study of mitoxantrone in solid tumors and lymphomasR De Jager, P Cappelaere, J P Armand, et al.
European Journal of Cancer & Clinical Oncology|February 1, 1983
Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-GroupR De Jager, P Siegenthaler, F Cavalli, et al.
Cancer Treatment Reports|June 1, 1985
Phase II study of elliptinium in advanced breast cancerJ G Rouësse, T Le Chevalier, P Caille, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary TuberculosisAndreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
British Journal of Clinical Pharmacology|June 29, 2018
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in childrenElin M Svensson, Jeannine du Bois, Rene Kitshoff, et al.
La Nouvelle Presse Medicale|January 9, 1982
[Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)]G Mathé, R de Jager, R Hulhoven, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Pageof 4